Variant · Snv

KRAS G12D

CI-VAR-00001606Explore in graph →NP_004976.2:p.Gly12AspNM_004985.4:c.35G>AClinVar 12582 CIViC 79 rs121913529

Curated evidence

Evidence by cancer (81 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 51–81 of 81 evidence items across 9 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Pancreatic Neoplasm9
KRAS G12D	(prognostic)	Prognostic	B	Supports Poor Outcome	4	accepted	EID1300 In 219 patients with metastatic pancreatic ductal adenocarcinoma, a multivariate analysis identified KRAS G12D mutations as an independent predictor of poorer prognosis both in patients that have rece… (full text at CIViC) PMID 27010960 · Bournet et al., 2016 · Open in CIViC	civic
KRAS G12D	(prognostic)	Prognostic	D	Supports Poor Outcome	4	submitted	EID7171 KRAS mutations are found in ∼90% of human pancreatic ductal adenocarcinomas. all mice with Kras G12D activation and Pten homozygous deletion succumbed to cancer by 3 weeks of age PMID 20807812 · Hill et al., 2010 · Open in CIViC	civic
KRAS G12D

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
12582	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts	2	Carcinoma of pancreas; Epidermal nevus; Nevus sebaceous; Linear nevus sebaceous syndrome; Juvenile myelomonocytic leukemia; Non-small cell lung carcinoma; Ovarian neoplasm; Acute myeloid leukemia; RASopathy; Cerebral arteriovenous malformation; Vascular Tumors Including Pyogenic Granuloma; Primary low grade serous adenocarcinoma of ovary; Encephalocraniocutaneous lipomatosis; Capillary malformation-arteriovenous malformation 1; Gastric cancer; Congenital Pulmonary Airway Malformations; Atypical endometrial hyperplasia; Endometrial hyperplasia without atypia; Neoplasm; Cardiovascular phenotype; Adenocarcinoma of the large intestine; Ovarian mucinous adenocarcinoma; Precursor B-cell acute lymphoblastic leukemia; Diffuse midline glioma, H3 K27M-mutant; Colorectal cancer; Medulloblastoma non-WNT/non-SHH; Glioma; RAS-ASSOCIATED AUTOIMMUNE LEUKOPROLIFERATIVE DISORDER 2, SOMATIC; Embryonal rhabdomyosarcoma; Papillary thyroid carcinoma; Alveolar rhabdomyosarcoma; Diffuse pediatric-type high-grade glioma, H3-wildtype and IDH-wildtype; KRAS-related disorder

Melanoma1
BRAF V600E AND KRAS G12D	Vemurafenib	Predictive	D	Supports Resistance	2	accepted	EID3957 In vitro studies of M229 (a human melanoma cell line) endogenously expressing wildtype KRAS and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over… (full text at CIViC) PMID 24265155 · Shi et al., 2014 · Open in CIViC	civic

Melanoma1

BRAF V600E AND KRAS G12D

Vemurafenib

Predictive

Supports Resistance

accepted

EID3957

In vitro studies of M229 (a human melanoma cell line) endogenously expressing wildtype KRAS and BRAF V600E (a known BRAF inhibitor sensitizing mutation) found that cells virally induced to stably over… (full text at CIViC)

PMID 24265155 · Shi et al., 2014 · Open in CIViC

Multiple Myeloma6
KRAS G12D	Melphalan	Predictive	B	Supports Resistance	2	rejected	EID2247 In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015). PMID 19284554 · Greco et al., 2009 · Open in CIViC	civic
KRAS G12D	Melphalan	Predictive	B	Supports Resistance	—	submitted	EID2248 Activating mutations in KRAS or NRAS were observed more frequently in multiple myeloma patients than in patients with monoclonal gammopathy of uncertain significance (MGUS) (31% vs. 5% ). Another stu… (full text at CIViC) PMID 11524732 · Bezieau et al., 2001 · Open in CIViC	civic
KRAS G12D	Melphalan	Predictive	B	Supports Resistance	—	submitted	EID2249 Activating mutations in KRAS or NRAS were observed more frequently in multiple myeloma patients than in patients with monoclonal gammopathy of uncertain significance (MGUS) (31% vs. 5% ). Another stu… (full text at CIViC) PMID 15339850 · Rasmussen et al., 2005 · Open in CIViC	civic
KRAS G12D	Melphalan	Predictive	D	Supports Resistance	2	accepted	EID2250 In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in compariso… (full text at CIViC) PMID 11050000 · Rowley et al., 2000 · Open in CIViC	civic
KRAS G12D	Melphalan	Predictive	D	Supports Resistance	—	accepted	EID2251 In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in compariso… (full text at CIViC) PMID 12483530 · Rowley et al., 2002 · Open in CIViC	civic
KRAS G12D	Melphalan	Predictive	D	Supports Resistance	2	accepted	EID2252 In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in compariso… (full text at CIViC) PMID 16497971 · Hoang et al., 2006 · Open in CIViC	civic

Pancreatic Ductal Adenocarcinoma10
ERBB2 L755S AND KRAS G12D	(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	submitted	EID11558 KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC	civic
ERBB2 R678Q AND KRAS G12D	(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	submitted	EID11552 KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC	civic
ERBB2 V777L AND KRAS G12D	(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	submitted	EID11560 KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC	civic
ERBB2 V842I AND KRAS G12D	(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	submitted	EID11562 KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC	civic
KRAS G12D	Adebrelimab + KRAS G12D Inhibitor HRS-4642Combination	Predictive	B	Supports Sensitivity Response	3	submitted	EID13294 In this phase 1/2 trial the KRAS G12D degrader HRS-4642 in combination with PD-L1 inhibitor adebrelimab was tested in 48 pretreated KRAS G12D-positive pancreatic adenocarcinoma patients. Patients had … (full text at CIViC) PMID 42748921 · Shi et al., 2026 · Open in CIViC	civic
KRAS G12D	Setidegrasib	Predictive	B	Supports Sensitivity Response	3	submitted	EID12938 A phase 1 dose‑escalation and dose‑expansion study in patients with previously treated advanced KRAS p.G12D mutant pancreatic ductal adenocarcinoma (NCT05382559; n = 203 overall; n = 21 PDAC treated a… (full text at CIViC) PMID 41879829 · Park et al., 2026 · Open in CIViC	civic
KRAS G12D AND ERBB2 E717D	(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	submitted	EID11556 KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC	civic
KRAS G12D AND ERBB2 Q679L	(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	submitted	EID11554 KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC	civic
KRAS G12D AND ERBB2 S310F	(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	submitted	EID11548 KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC	civic
KRAS G12D AND ERBB2 S423R	(oncogenic)	Oncogenic	D	Supports Oncogenicity	3	submitted	EID11550 KRAS G12D-transformed HPNE cells with lentiviral vectors containing the variant significantly increased colony formation in number and size in soft agar compared to infected HPNE cells with the varian… (full text at CIViC) PMID 31046123 · Li et al., 2020 · Open in CIViC	civic